Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab concentrations in breast milk after subcutaneous maintenance dosing in lactating women
MOH_2026-05-19_015831Phase 4Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mirikizumab in autoimmune colitis and Crohn's disease, sponsored by Eli Lilly and Company. Primary endpoint: Mirikizumab concentration in breast milk. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
mirikizumab
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on MOH_2026-05-19_015831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-05-19_015831.